Focus: Fractyl Health is a biotech company specializing in thermal ablation therapy and gene therapy, focused on metabolic diseases including Type 2 Diabetes, obesity, and NASH. The company is publicly traded on NASDAQ under ticker GUTS and operates from Burlington, MA.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Fractyl offers exposure to innovative thermal-ablation therapy in a high-growth metabolic-disease space, but litigation and minimal hiring signal near-term organizational caution.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Fractyl Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fractyl Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Fractyl Health - The Pharmaletter
Fractyl Health The Pharmaletter
Fractyl Health, Inc. (NASDAQ: GUTS) Investor Alert: Deadline in Lawsuit on October 20, 2026 - openPR.com
Fractyl Health, Inc. (NASDAQ: GUTS) Investor Alert: Deadline in Lawsuit on October 20, 2026 openPR.com
Class action lawsuit filed against Fractyl Heal... - Pluang
Class action lawsuit filed against Fractyl Heal... Pluang
Class action lawsuit filed against Fractyl Heal... - Pluang
Class action lawsuit filed against Fractyl Heal... Pluang
H.C. Wainwright Sticks to Their Buy Rating for Fractyl Health, Inc. (GUTS) - The Globe and Mail
H.C. Wainwright Sticks to Their Buy Rating for Fractyl Health, Inc. (GUTS) The Globe and Mail
Shareholders Sue Fractyl (GUTS) Over Weight Loss Drug Claims - TipRanks
Shareholders Sue Fractyl (GUTS) Over Weight Loss Drug Claims TipRanks
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo